A detailed history of Qube Research & Technologies LTD transactions in Exelixis, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 480,576 shares of EXEL stock, worth $12.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
480,576
Previous 16,079 2888.84%
Holding current value
$12.9 Million
Previous $381,000 2734.12%
% of portfolio
0.02%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$20.34 - $23.73 $9.45 Million - $11 Million
464,497 Added 2888.84%
480,576 $10.8 Million
Q4 2023

Feb 13, 2024

SELL
$19.25 - $24.13 $1.91 Million - $2.39 Million
-99,217 Reduced 86.05%
16,079 $385,000
Q3 2023

Nov 13, 2023

BUY
$19.04 - $22.74 $1.82 Million - $2.17 Million
95,460 Added 481.25%
115,296 $2.52 Million
Q2 2023

Aug 14, 2023

BUY
$18.17 - $20.48 $360,420 - $406,241
19,836 New
19,836 $379,000
Q4 2022

Feb 14, 2023

BUY
$14.96 - $17.39 $5.42 Million - $6.3 Million
362,209 Added 27.68%
1,670,991 $26.8 Million
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $16.4 Million - $23.4 Million
1,048,698 Added 403.22%
1,308,782 $20.5 Million
Q2 2022

Aug 15, 2022

BUY
$17.44 - $23.16 $4.54 Million - $6.02 Million
260,084 New
260,084 $5.42 Million
Q1 2022

May 09, 2022

SELL
$17.03 - $22.67 $452,333 - $602,137
-26,561 Closed
0 $0
Q4 2021

Feb 01, 2022

BUY
$15.84 - $21.88 $420,726 - $581,154
26,561 New
26,561 $486,000
Q2 2021

Aug 13, 2021

SELL
$17.95 - $25.56 $763,341 - $1.09 Million
-42,526 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$20.53 - $25.22 $873,058 - $1.07 Million
42,526 New
42,526 $961,000
Q4 2020

Feb 16, 2021

SELL
$18.39 - $24.8 $1.32 Million - $1.78 Million
-71,642 Closed
0 $0
Q3 2020

Nov 12, 2020

SELL
$20.67 - $26.94 $3.06 Million - $3.98 Million
-147,807 Reduced 67.35%
71,642 $1.75 Million
Q2 2020

Aug 14, 2020

BUY
$16.46 - $27.42 $3.37 Million - $5.61 Million
204,646 Added 1382.46%
219,449 $5.21 Million
Q1 2020

May 15, 2020

BUY
$14.46 - $21.8 $214,051 - $322,705
14,803 New
14,803 $255,000
Q4 2019

Feb 13, 2020

SELL
$15.15 - $18.89 $188,102 - $234,538
-12,416 Closed
0 $0
Q3 2019

Nov 13, 2019

SELL
$17.68 - $22.65 $42,714 - $54,722
-2,416 Reduced 16.29%
12,416 $220,000
Q2 2019

Aug 02, 2019

BUY
$18.93 - $24.75 $280,769 - $367,092
14,832 New
14,832 $317,000
Q4 2018

Feb 14, 2019

SELL
$13.65 - $21.8 $142,847 - $228,137
-10,465 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$15.87 - $22.4 $166,079 - $234,415
10,465 New
10,465 $185,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $8.63B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.